Full Press Release Details
Supernus to Present at the 2018 Jefferies Healthcare Conference
ROCKVILLE, Md., May 30, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will present an overview and update of the Company s business, and host investor meetings at the Jefferies 2018 Global Healthcare Conference.
Date: Tuesday, June 5, 2018
Place: Grand Hyatt New York in New York City
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company s website.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine headache and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com